89% of KLAS-surveyed customers use Xsolis’ AI technology to minimize preventable denials.
Many medical device companies want to go to Japan since it is the third-largest market in the world. Oftentimes, device companies want to register their devices quickly in Japan to be on the market and are not focused enough on the initial medical device reimbursement they will get. This can lead to an unprofitable business if the Japanese reimbursement price is not higher than the sales price in Japan. Are there strategies to increase reimbursement?
Medical Devices must be fully reimbursable – no out of pocket expenses – in Japan. So, how is reimbursement achieved for your medical device?
careviso Survey Highlights Major Communication Gaps in Healthcare, Impacting Financial Transparency and Patient Experience
Billions of dollars are lost annually in medical billing errors resulting from data entry mistakes, outdated coding practices, and duplicated charges. Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing the process of claims processing, diagnostics, eliminating errors, streamlining workflow, and increasing the accuracy of claims submissions. Together with human oversight to ensure precision and safety, AI augments healthcare professionals to improve patient care and outcomes.
In the face of sweeping Medicare changes for 2025, millions of seniors face the challenge of navigating a complex landscape of new options, increased costs, and altered benefits. Innovative technologies are emerging as crucial tools for both patients and healthcare providers, offering detailed cost comparisons, network analyses, and benefit breakdowns.
Medical Device reimbursement levels in Japan are now more in line with the reimbursement levels in the EU. The Japanese government has pledged not to allow Japanese device reimbursement to be as high as the US prices.
Congress must decide the future of the Acute Hospital Care at Home (AHCAH) program, an initiative of the Centers for Medicare & Medicaid Services (CMS) that, without legislative action, will expire on December 31, 2024. To ensure beneficiaries can receive various levels of care in their preferred settings, this brief provides immediate–term federal policy reform recommendations for the potential reauthorization of the AHCAH model while outlining key issues for policymakers to consider when further research and data emerge.
As medical technology products and services move through the development pipeline, they face the challenge of both showing safety and efficacy for regulatory approval and articulating the value of the diagnostic, treatment or monitoring technology to obtain reimbursement from payers. A 2024 MedExec Women Conference panel highlighted strategies to bridge the evidence needs for regulatory approval and reimbursement to more efficiently bring products to market.
Payers demand robust evidence that molecular diagnostics and AI/ML technologies demonstrate clear ability to improve overall patient health or healthcare economics even if the technologies themselves don’t directly deliver the final outcome. This disconnect between a technology’s function and the desired long-term impact creates a hurdle for [innovators] to overcome when convincing payers of their value proposition.
